Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a first-in-human Phase 1/2 trial registration with no results posted; it describes planned enrollment and primary endpoints focused on safety, tolerability, and pharmacokinetics in an early-stage investigation of a novel PRMT5 inhibitor.
First-in-patient Phase 1 safety and dose-finding study with no results posted; designed to establish safety and tolerability of BAY 3389934 in sepsis-induced coagulopathy.
This is a first-in-human Phase 1/2 trial registration with no results reported; the study is actively recruiting and designed to establish safety, tolerability, and preliminary efficacy of a novel dual EGFR/HER2 inhibitor in advanced NSCLC.
This is a first-in-human Phase 1 dose-escalation study with safety and pharmacokinetic endpoints; no results are posted in this registry record, so the evidence base is not yet available for assessment.